{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:00:43Z","timestamp":1764079243819,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,3,27]],"date-time":"2017-03-27T00:00:00Z","timestamp":1490572800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s00280-017-3284-y","type":"journal-article","created":{"date-parts":[[2017,3,27]],"date-time":"2017-03-27T04:32:24Z","timestamp":1490589144000},"page":"915-922","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR"],"prefix":"10.1007","volume":"79","author":[{"given":"Wijith P.","family":"Munasinghe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajendar K.","family":"Mittapalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle D.","family":"Holen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev M.","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,27]]},"reference":[{"issue":"5","key":"3284_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/08977190802312844","volume":"26","author":"AW Burgess","year":"2008","unstructured":"Burgess AW (2008) EGFR family: structure physiology signalling and therapeutic targets. Growth Factors 26(5):263\u2013274","journal-title":"Growth Factors"},{"issue":"1","key":"3284_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.tcb.2013.11.002","volume":"24","author":"A Tomas","year":"2014","unstructured":"Tomas A, Futter CE, Eden ER (2014) EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol 24(1):26\u201334","journal-title":"Trends Cell Biol"},{"issue":"7","key":"3284_CR3","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","volume":"22","author":"LB Saltz","year":"2004","unstructured":"Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22(7):1201\u20131208","journal-title":"J Clin Oncol"},{"issue":"7","key":"3284_CR4","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/annonc\/mdu141","volume":"25","author":"JY Douillard","year":"2014","unstructured":"Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Tian Y, Xu F, Sidhu R (2014) Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 25(7):1346\u20131355","journal-title":"Ann Oncol"},{"issue":"2","key":"3284_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11523-013-0271-z","volume":"8","author":"M Poulin-Costello","year":"2013","unstructured":"Poulin-Costello M, Azoulay L, Van Cutsem E, Peeters M, Siena S, Wolf M (2013) An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer. Target Oncol 8(2):127\u2013136","journal-title":"Target Oncol"},{"issue":"20","key":"3284_CR6","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357(20):2040\u20132048","journal-title":"N Engl J Med"},{"issue":"11","key":"3284_CR7","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359(11):1116\u20131127","journal-title":"N Engl J Med"},{"issue":"2","key":"3284_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123\u2013132","journal-title":"N Engl J Med"},{"issue":"15","key":"3284_CR9","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15):1960\u20131966","journal-title":"J Clin Oncol"},{"key":"3284_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.bcp.2016.06.014","volume":"122","author":"MF Emmons","year":"2016","unstructured":"Emmons MF, Faiao-Flores F, Smalley KS (2016) The role of phenotypic plasticity in the escape of cancer cells from targeted therapy. Biochem Pharmacol 122:1\u20139","journal-title":"Biochem Pharmacol"},{"key":"3284_CR11","doi-asserted-by":"publisher","first-page":"10091028","DOI":"10.1016\/j.tips.2016.09.005","volume":"37","author":"BV Ayyar","year":"2016","unstructured":"Ayyar BV, Arora S, O\u2019Kennedy R (2016) Coming-of-Age of Antibodies in Cancer Therapeutics. Trends Pharmacol Sci 37:1009\u20131028","journal-title":"Trends Pharmacol Sci"},{"key":"3284_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-016-0323-0","author":"K Tsuchikama","year":"2016","unstructured":"Tsuchikama K, An Z (2016) Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. doi:\n                        10.1007\/s13238-016-0323-0","journal-title":"Protein Cell"},{"issue":"12","key":"3284_CR13","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","volume":"15","author":"F Loganzo","year":"2016","unstructured":"Loganzo F, Sung M, Gerber HP (2016) Mechanisms of resistance to antibody-drug conjugates. Mol Cancer Ther 15(12):2825\u20132834","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"3284_CR14","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1158\/1535-7163.MCT-15-0901","volume":"15","author":"AC Phillips","year":"2016","unstructured":"Phillips AC, Boghaert ER, Vaidya KS, Mitten MJ, Norvell S, Falls HD, DeVries PJ, Cheng D, Meulbroek JA, Buchanan FG, McKay LM, Goodwin NC, Reilly EB (2016) ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope. Mol Cancer Ther 15(4):661\u2013669","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"3284_CR15","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1158\/0008-5472.CAN-11-3898","volume":"72","author":"HK Gan","year":"2012","unstructured":"Gan HK, Burgess AW, Clayton AH, Scott AM (2012) Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res 72(12):2924\u20132930","journal-title":"Cancer Res"},{"issue":"5","key":"3284_CR16","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/1535-7163.MCT-14-0820","volume":"14","author":"EB Reilly","year":"2015","unstructured":"Reilly EB, Phillips AC, Buchanan FG, Kingsbury G, Zhang Y, Meulbroek JA, Cole TB, DeVries PJ, Falls HD, Beam C, Gu J, Digiammarino EL, Palma JP, Donawho CK, Goodwin NC, Scott AM (2015) Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther 14(5):1141\u20131151","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"3284_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11523-009-0114-0","volume":"4","author":"T Li","year":"2009","unstructured":"Li T, Perez-Soler R (2009) Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 4(2):107\u2013119","journal-title":"Target Oncol"},{"key":"3284_CR18","unstructured":"Guidance for Industry E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. October 2005 ICH. \n                        https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM073153.pdf\n                        \n                    . Accessed 8 Feb 2017"},{"issue":"4","key":"3284_CR19","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/cpt.60","volume":"97","author":"B Darpo","year":"2015","unstructured":"Darpo B, Benson C, Dota C, Ferber G, Garnett C, Green CL, Jarugula V, Johannesen L, Keirns J, Krudys K, Liu J, Ortemann-Renon C, Riley S, Sarapa N, Smith B, Stoltz RR, Zhou M, Stockbridge N (2015) Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase. Clin Pharmacol Ther 97(4):326\u2013335","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"3284_CR20","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ahj.2014.06.003","volume":"168","author":"B Darpo","year":"2014","unstructured":"Darpo B, Garnett C, Benson CT, Keirns J, Leishman D, Malik M, Mehrotra N, Prasad K, Riley S, Rodriguez I, Sager P, Sarapa N, Wallis R (2014) Cardiac Safety Research Consortium: can the thorough QT\/QTc study be replaced by early QT assessment in routine clinical pharmacology studies? Scientific update and a research proposal for a path forward. Am Heart J 168(3):262\u2013272","journal-title":"Am Heart J"},{"key":"3284_CR21","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2005) ICH Harmonised tripartite guideline. The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. E14. \n                        http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E14\/E14_Guideline.pdf\n                        \n                    . Accessed 8 Feb 2017"},{"key":"3284_CR22","unstructured":"International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. E14 Implementation Working Group (2015). ICH E14 guideline: the clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Questions and answers (R3). \nhttp:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E14\/E14_Q_As_R3__Step4.pdf\n\n. Accessed 8 Feb 2017"},{"issue":"1","key":"3284_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00280-013-2192-z","volume":"72","author":"TH Han","year":"2013","unstructured":"Han TH, Chen R, Advani R, Berryman RB, Smith SE, Forero-Torres A, Rosenblatt JD, Smith MR, Zain J, Hunder NN, Engert A (2013) Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies. Cancer Chemother Pharmacol 72(1):241\u2013249","journal-title":"Cancer Chemother Pharmacol"},{"key":"3284_CR24","doi-asserted-by":"publisher","unstructured":"Gupta M, Wang B, Carrothers TJ, LoRusso PM, Chu YW, Shih T, Loecke D, Joshi A, Saad O, Yi JH, Girish S (2013) Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Clin Pharmacol Drug Dev 2(1):11\u201324","DOI":"10.1002\/cpdd.9"},{"issue":"3","key":"3284_CR25","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10637-015-0234-6","volume":"33","author":"JM Cleary","year":"2015","unstructured":"Cleary JM, Reardon DA, Azad N, Gandhi L, Shapiro GI, Chaves J, Pedersen M, Ansell P, Ames W, Xiong H, Munasinghe W, Dudley M, Reilly EB, Holen K, Humerickhouse R (2015) A phase 1 study of ABT-806 in subjects with advanced solid tumors. Invest New Drugs 33(3):671\u2013678","journal-title":"Invest New Drugs"},{"issue":"10","key":"3284_CR26","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s40262-015-0258-2","volume":"54","author":"S Sharma","year":"2015","unstructured":"Sharma S, Mittapalli RK, Holen KD, Xiong H (2015) Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR. Clin Pharmacokinet 54(10):1071\u20131081","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"3284_CR27","first-page":"1204","volume":"7","author":"DM Shin","year":"2001","unstructured":"Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers J, Clayman G, Pfister D, Falcey J, Waksal H, Mendelsohn J, Hong WK (2001) Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 7(5):1204\u20131213","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3284_CR28","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1200\/JCO.2000.18.4.904","volume":"18","author":"J Baselga","year":"2000","unstructured":"Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D\u2019Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J (2000) Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18(4):904\u2013914","journal-title":"J Clin Oncol"},{"issue":"11","key":"3284_CR29","doi-asserted-by":"publisher","first-page":"729","DOI":"10.2165\/11535970-000000000-00000","volume":"49","author":"BB Yang","year":"2010","unstructured":"Yang BB, Lum P, Chen A, Arends R, Roskos L, Smith B, Perez Ruixo JJ (2010) Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. Clin Pharmacokinet 49(11):729\u2013740","journal-title":"Clin Pharmacokinet"},{"issue":"21","key":"3284_CR30","doi-asserted-by":"publisher","first-page":"6517","DOI":"10.1158\/1078-0432.CCR-06-0705","volume":"12","author":"AR Tan","year":"2006","unstructured":"Tan AR, Moore DF, Hidalgo M, Doroshow JH, Poplin EA, Goodin S, Mauro D, Rubin EH (2006) Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res 12(21):6517\u20136522","journal-title":"Clin Cancer Res"},{"issue":"15","key":"3284_CR31","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1200\/JCO.2004.11.061","volume":"22","author":"EK Rowinsky","year":"2004","unstructured":"Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, Bukowski R, Haas N, Lockbaum P, Li YP, Arends R, Foon KA, Schwab G, Dutcher J (2004) Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22(15):3003\u20133015","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3284-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3284-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3284-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T06:10:56Z","timestamp":1493014256000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3284-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,27]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["3284"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3284-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2017,3,27]]}}}